跳至主要内容
临床试验/NCT01736865
NCT01736865已完成2 期

Vitamin D for Established Type 2 Diabetes (DDM2)

Tufts Medical Center2 个研究点 分布在 1 个国家目标入组 127 人开始时间: 2012年12月最近更新:
适应症
干预措施
相关药物

试验速览

阶段
2 期
状态
已完成
入组人数
127
试验地点
2
主要终点
Disposition Index

研究概览

简要总结

This research study in adults with established type 2 diabetes will test whether daily vitamin D supplementation affects how the body processes glucose (sugar).

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)

入排标准

年龄范围
25 Years 至 75 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Established type 2 diabetes, defined by one of the following two criteria:
  • Age ≥ 25 years and ≤ 75 years
  • BMI: 23 to 40 kg/m2 inclusive
  • Provision of signed and dated written informed consent prior to any study procedures.
  • Major Exclusion Criteria
  • "Severe" diabetes defined by one of the following criteria:
  • - (a) Symptoms of hyperglycemia;
  • - (b) Screening HbA1c ≥ 7.5 [may indicate potential for rapid progression during the trial necessitating need to amplify diabetes-specific pharmacotherapy]
  • History of nephrolithiasis or hypercalcemia

排除标准

  • 未提供

研究组 & 干预措施

placebo

Placebo Comparator

One placebo pill daily for 1 year

干预措施: Placebo (Drug)

cholecalciferol

Active Comparator

One cholecalciferol pill daily for 1 year

干预措施: Cholecalciferol (Drug)

结局指标

主要结局

Disposition Index

时间窗: 6 months

Disposition index by the insulin secretion sensitivity index-2 (ISSI-2). This is an calculated value which represents the ability of a person's pancreatic beta cells to lower blood glucose. A higher number means the pancreas is better able to secrete insulin and improve glucose levels.

次要结局

  • Number of Participants With Change in Glycemia(12 months)

研究者

申办方类型
Other
责任方
Sponsor

研究点 (2)

Loading locations...

相似试验